Cancer Therapies

Intro

RGCC (Research Genetics Cancer Center Group) is the name of a cancer research facility founded in 2004 by Dr. Ioannis Papasotitiou. This facility offers cutting-edge ways of detecting early cancers, maximizing effectiveness of therapies, monitoring cancers for progression or occurrence, and enhancing the body’s ability to destroy cancer cells.

Its state-of-the-art research and development gives patients the ability to detect cancer cells in the circulation (also known as circulating tumor cells or CTCs), even if no solid tumor is yet formed.

Technology called flow cytometry isolates these CTCs with a 97-99% purity, allowing the cells to undergo further molecular and genetic analysis. These CTCs can be tested for aggressiveness, resistance, and response to therapy. RGCC can also offer extremely helpful testing that predicts the cancer cells’ sensitivity or resistance to various chemotherapies or NATURAL substances. This helps take the guesswork out of treatment protocols and allows patients and providers to utilize the most effective therapies possible.

RGCC also offers treatments that help the body fight and destroy cancer cells without chemotherapy by shutting down cellular replication (SOT) or mounting a specific immune response to the cells (Dendritic Cell Therapy and VAX-Q-RE)

SOT is a therapy by which cancer-causing genes are silenced and prevented from replicating. With this treatment, a person’s specific genes are analyzed, the cancer-causing mutations are identified, and a specific, individualized treatment is created to “inactivate” those genes that are causing uncontrolled replication of the cancer cells.

The RGCC lab located in Greece has developed a process that enables them to identify the specific gene sequences of different targets such as cancer, Lyme disease, and viruses.

• The term “gene sequences” refers to specific sections of DNA that encode for the production of specific proteins that determine how cells function and replicate.
• The information stored in DNA is communicated to the cells via strands of genetic material called mRNA (messenger RNA). This mRNA dictates which proteins are made by the cells.
• Normal cells (with healthy DNA and proteins) contain mechanisms that tightly control cellular replication, ensuring that those cells that are cancerous, infected, or otherwise unhealthy are destroyed and do not get propagated.
• Mutations in the DNA can lead to the production of harmful proteins that cause disease, including cancer. Cancer cells lack the “controls” associated with proper replication and this leads to unchecked, uncontrolled growth.
• SOT targets the mRNA associated with cancer cells by binding to specific sequences, rendering them incapable of making the proteins necessary for replication.
• This causes the cancer cells to die without being able to make more cancer cells. The process by which they die is known as “apoptosis.”

Nagalase is an enzyme that plays a significant role in cancer, Lyme disease, Epstein-Barr virus, and other chronic debilitating infections. It is an immunosuppressive enzyme that hinders the immune system’s ability to detect and destroy mutated and infected cells, allowing them to replicate and spread.

Nagalase weakens the immune response by decreasing the production of an immune-stimulating molecule called Gc-MAF. It does this by breaking down Gc-MAF’s precursor protein (called Gc-protein or vitamin D binding protein), preventing it from being turned into Gc-MAF. When this happens, the immune system fails to recognize and attack destructive and diseased cells, allowing them to continue growing and spreading. For this reason, nagalase is sometimes called cancer’s cloak of invisibility.

Cancer cells, Lyme bacteria, and certain viruses produce nagalase as part of their survival strategy. Understanding of this has led to better options for natural treatments that will support the immune system instead of tearing it down. Nagalase can be detected through a simple blood test, and if levels are elevated they can be treated with a specific substance called Salicinium.

One of the greatest advancements in cancer research was provided by Dr. Otto Warburg, a German biochemist who won the Nobel Prize for Physiology/Medicine in 1931 for his research on the cellular process for making energy (aka cellular respiration).

He discovered the phenomenon whereby cancer cells switch their mode of energy production from an oxygen-dependent process called “oxidative phosphorylation” to a sugar-dependent process called “glycolysis.” In other words, he was the one to discover that cancer cells feed off of sugar. This phenomenon would later become known as the Warburg effect.